Lung cancer ranks first both in mobidity and motality in china and worldwild. Squamous cell lung carcinoma is distinguished from lung adenocarcinoma in diagnosis and treatment due to its unique clinical & pathological manifestations and gene mutation characteristics, as a result, it is also explored as a separate type in clinical researches. In addition to the clinical manifestations of elderly, central tumors, late staging at diagnosis, and multiple comorbidities, the lack of driver genes makes it nearly impossible for these patients to benefit from targeted therapy. However, the exploration of targeted therapy for lung squamous cell carcinoma has never stopped. Several new drugs including fibroblast growth factor receptor tyrosine kinase inhibitor and cyclin dependent kinase 4 and 6 inhibitors have been studied in multiple phase I studies specifically in patients with lung squamous cell carcinoma. However, with the development of immunotherapy, the characteristics such as complex gene mutation and high tumor mutation burden makes it possible for patients with squamous cell lung cancer to benefit from immunotherapy combined with chemotherapy. This review will provide an overview of the treatment progress in advanced squamous cell lung cancer including chemotherapy, targeted therapy and immunotherapy. .
【中文题目：晚期肺鳞癌治疗进展】 【中文摘要：肺癌是世界及中国发病率和死亡率第一的恶性肿瘤，肺鳞癌因其独特的临床表现、病理表现及基因突变特征，在诊治中与肺腺癌的区别显著，在临床研究中也作为单独的类型进行探索。除了肺鳞癌常表现为高龄、中央型肿瘤、诊断分期晚、合并症多，其往往少有驱动基因突变使得靶向治疗难以在肺鳞癌患者中获益，但是对于肺鳞癌的靶向治疗探索并未停止，包括纤维母细胞生长因子受体-酪氨酸激酶抑制剂和细胞周期蛋白依赖性激酶4和6抑制剂等新药在肺鳞癌患者中进行了多项I期研究。但随着免疫治疗的发展，鳞癌患者因其基因突变复杂，肿瘤突变负荷高等特点，免疫治疗联合化疗终于使肺鳞癌患者的预后有所改善。本文旨在从化疗、靶向治疗、抗血管治疗及免疫治疗几方面综述近年来晚期肺鳞癌的治疗进展。 】 【中文关键词：肺肿瘤；化疗；靶向治疗；免疫治疗】.
Keywords: Chemotherapy; Immunotherapy; Lung neoplasms; Targeted therapy.